Mike Warmuth joined EW as an Operating Partner in 2018 after 30+ years with Abbott Laboratories, where he spent his entire career.
Mr. Warmuth has played a key role in building EW’s pharmaceutical investment practice. He served on the Board of Directors for Cognate Bioservices before it was acquired by Charles River Laboratories in March 2021.
Prior to joining EW, Mr. Warmuth most recently spent five years as Executive Vice President, leading Abbott’s Established Pharmaceuticals division, which is a leader in the sale of branded generics in emerging markets. The Established Pharmaceuticals division of Abbott is among the top ten largest generics companies globally, with revenues of >$4 billion. Prior to running Established Pharmaceuticals, Mr. Warmuth spent almost three years as the Senior Vice President of Diagnostics, running Abbott’s global core laboratory diagnostics business. Prior thereto, Mr. Warmuth spent a brief period as GM for the Hematology division within the Diagnostics business unit. Before this, he was Vice President of the Global Engineering Services business. From 2004 to 2006, he was Division VP, Operations for the Quality and Global Pharmaceutical Operations team.
Mr. Warmuth received his Bachelor of Business Administration degree from the University of Wisconsin-Whitewater and his Master of Business Administration degree from Northwestern University.